Petreni P - Search Results

1

Somatostatin analogs in pregnant patients with neuroendocrine tumor.

Meoni G, Giommoni E, Petreni P, Pillozzi S, Mazzoni F, Pellegrini E, Brugia M, Lunghi A, Muto A, Antonuzzo L. Meoni G, et al. Among authors: petreni p. Anticancer Drugs. 2020 Nov;31(10):1096-1098. doi: 10.1097/CAD.0000000000000967. Anticancer Drugs. 2020. PMID: 32590392

2

Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification.

Meoni G, Antonuzzo L, Messerini L, Giommoni E, Muto A, Petreni P, Vannini A, Lunghi A, Molinara E, Di Costanzo F. Meoni G, et al. Among authors: petreni p. Endocr J. 2014;61(10):989-94. doi: 10.1507/endocrj.ej14-0191. Epub 2014 Aug 2. Endocr J. 2014. PMID: 25088492 Free article.

3

Outcome of crizotinib treatment in a young woman with heavily pretreated ROS1-positive lung cancer.

Petreni P, Mazzoni F, Meoni G, Lunghi A, Cecere FL, Muto A, Di Costanzo F. Petreni P, et al. Tumori. 2015 Jun 25;101(3):e103-6. doi: 10.5301/tj.5000288. Tumori. 2015. PMID: 25908037

4

In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations".

Caliman E, Petreni P, Brugia M, Antonuzzo L, Mazzoni F. Caliman E, et al. Among authors: petreni p. Clin Lung Cancer. 2020 Sep;21(5):e363-e365. doi: 10.1016/j.cllc.2020.02.002. Epub 2020 Feb 8. Clin Lung Cancer. 2020. PMID: 32143968 No abstract available.

5

A new proteomic test could guide treatment decision in second-line therapy for patients with EGFR unselected non-small cell lung cancer?

Mazzoni F, Petreni P, Lunghi A. Mazzoni F, et al. Among authors: petreni p. Ann Transl Med. 2015 Mar;3(3):30. doi: 10.3978/j.issn.2305-5839.2015.01.03. Ann Transl Med. 2015. PMID: 25815291 Free PMC article. No abstract available.

6

Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.

Antonuzzo L, Lunghi A, Petreni P, Brugia M, Laffi A, Giommoni E, Mela MM, Mazzoni F, Balestri V, Costanzo FD. Antonuzzo L, et al. Among authors: petreni p. Curr Med Chem. 2017;24(28):3068-3076. doi: 10.2174/0929867324666170511113811. Curr Med Chem. 2017. PMID: 28494743 Review.

7

ROS1 rearrangements are uncommon in biliary tract cancers.

Mazzoni F, Petreni P, Vasile E, Panebianco M, Casadei-Gardini A, Negri F, Lunghi A, Pillozzi S, Vivaldi C, Gervasi E, Frassineti GL, Messerini L, Jocollé G, Bisagni A, Antonuzzo L, Rossi G. Mazzoni F, et al. Among authors: petreni p. Oncol Lett. 2020 Dec;20(6):316. doi: 10.3892/ol.2020.12179. Epub 2020 Oct 1. Oncol Lett. 2020. PMID: 33133252 Free PMC article.

8

First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.

Camerini A, Chella A, Mazzoni F, Puccetti C, Donati S, Lunghi A, Petreni P, Tartarelli G, Serradori M, Di Costanzo F, Amoroso D. Camerini A, et al. Among authors: petreni p. J Chemother. 2017 Feb;29(1):38-41. doi: 10.1080/1120009X.2016.1219498. Epub 2016 Aug 16. J Chemother. 2017. PMID: 27687319

9

Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences.

Mazzoni F, Petreni P, Perna M, Scotti V, Bongiolatti S, Livi L, Di Costanzo F, Voltolini L. Mazzoni F, et al. Among authors: petreni p. Tumori. 2018 Dec;104(6):NP5-NP9. doi: 10.1177/0300891618775204. Epub 2018 Jun 13. Tumori. 2018. PMID: 29895214

10

Emerging drugs in refractory colorectal cancer.

Nobili S, Galletta A, Brugia M, Tassi R, Petreni P, Landini I, Mini E. Nobili S, et al. Among authors: petreni p. Future Med Chem. 2015 Aug;7(12):1491-501. doi: 10.4155/fmc.15.85. Epub 2015 Aug 21. Future Med Chem. 2015. PMID: 26293581 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page